GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (FRA:AWK) » Definitions » Cyclically Adjusted PB Ratio

Avadel Pharmaceuticals (FRA:AWK) Cyclically Adjusted PB Ratio : 6.52 (As of Jun. 01, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Avadel Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2025-06-01), Avadel Pharmaceuticals's current share price is €7.95. Avadel Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was €1.22. Avadel Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 6.52.

The historical rank and industry rank for Avadel Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:AWK' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.87   Med: 6.83   Max: 14.15
Current: 6.94

During the past years, Avadel Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 14.15. The lowest was 0.87. And the median was 6.83.

FRA:AWK's Cyclically Adjusted PB Ratio is ranked worse than
89.63% of 694 companies
in the Drug Manufacturers industry
Industry Median: 1.94 vs FRA:AWK: 6.94

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Avadel Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2025 was €0.709. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €1.22 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Avadel Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Avadel Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avadel Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Avadel Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.95 6.53 5.92 10.35 8.08

Avadel Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.75 10.72 10.15 8.08 5.96

Competitive Comparison of Avadel Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Avadel Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avadel Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avadel Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Avadel Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


;
;

Avadel Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Avadel Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=7.95/1.22
=6.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avadel Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Avadel Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.709/123.4051*123.4051
=0.709

Current CPI (Mar. 2025) = 123.4051.

Avadel Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201506 0.300 100.573 0.368
201509 0.000 100.274 0.000
201512 1.539 99.676 1.905
201603 1.518 99.676 1.879
201606 1.119 101.072 1.366
201609 0.796 100.274 0.980
201612 0.964 99.676 1.193
201703 1.335 100.374 1.641
201706 1.704 100.673 2.089
201709 2.035 100.474 2.499
201712 1.838 100.075 2.266
201803 1.876 100.573 2.302
201806 1.830 101.072 2.234
201809 1.522 101.371 1.853
201812 0.065 100.773 0.080
201903 -0.227 101.670 -0.276
201906 -0.421 102.168 -0.509
201909 -0.654 102.268 -0.789
201912 -0.700 102.068 -0.846
202003 0.625 102.367 0.753
202006 2.782 101.769 3.373
202009 2.495 101.072 3.046
202012 2.284 101.072 2.789
202103 1.960 102.367 2.363
202106 1.687 103.364 2.014
202109 1.435 104.859 1.689
202112 1.181 106.653 1.366
202203 0.849 109.245 0.959
202206 -0.053 112.779 -0.058
202209 -0.206 113.504 -0.224
202212 -0.318 115.436 -0.340
202303 -0.553 117.609 -0.580
202306 1.479 119.662 1.525
202309 1.154 120.749 1.179
202312 0.895 120.749 0.915
202403 0.750 120.990 0.765
202406 0.679 122.318 0.685
202409 0.698 121.594 0.708
202412 0.731 122.439 0.737
202503 0.709 123.405 0.709

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Avadel Pharmaceuticals  (FRA:AWK) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Avadel Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Avadel Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Avadel Pharmaceuticals Business Description

Traded in Other Exchanges
Address
10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.